XML 83 R65.htm IDEA: XBRL DOCUMENT v3.20.4
Theravance Respiratory Company, LLC (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 21, 2020
Oct. 31, 2021
USD ($)
Jan. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Oct. 31, 2020
USD ($)
Theravance Respiratory Company, LLC                
Equity method investments       $ 12,750,000 $ 12,750,000     $ 12,800,000
TRC                
Theravance Respiratory Company, LLC                
Percentage of equity interest       85.00% 85.00%      
Percentage of economic interest 85.00%       85.00%      
Number of fiscal quarters         4      
Payments to Acquire Equity Method Investments   $ 15,000,000.0            
Amount due       $ 53,800,000 $ 53,800,000      
Royalty payments         68,400,000 $ 33,700,000 $ 11,200,000  
Royalty expenses         2,200,000 $ 2,700,000    
Termination fees         $ 8,500,000      
TRC | Arbitration against Innoviva and TRC                
Theravance Respiratory Company, LLC                
Percentage of economic interest         0.85%      
Innoviva                
Theravance Respiratory Company, LLC                
Partial distribution of funds     $ 21,300,000 $ 2,500,000